GlassScriptPhysician profile
Robert A Mcpike
NPI 1437507282
$1,608.25
in general payments reported to CMS, 2019-2025
24 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $163 · 2021: $217 · 2022: $188 · 2023: $220 · 2024: $368 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $860.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $272.10 | 2019-2025 | Rocklatan, Clareon |
| Regeneron Healthcare Solutions, INC. | $208.01 | 2021-2025 | Eylea Hd, Eylea |
| Bausch & Lomb Americas INC. | $141.15 | 2022-2025 | Xiidra, Miebo, Alrex |
| Aerie Pharmaceuticals, INC. | $118.39 | 2020-2021 | |
| Genentech USA, INC. | $111.93 | 2023-2025 | Vabysmo |
| Horizon Therapeutics Plc | $98.40 | 2019-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $87.46 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $73.95 | 2024-2025 | Xdemvy |
| Thea Pharma INC. | $65.27 | 2022-2024 | Iyuzeh |
| Abbvie INC. | $49.94 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $48.28 | 2019-2022 | |
| Biotissue Holdings INC. | $46.48 | 2020-2024 | |
| Harrow Eye, LLC | $44.99 | 2024 | Triesence, Iheezo |
| Astellas Pharma US INC | $36.03 | 2023-2025 | Izervay |
| Allergan, INC. | $28.92 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tearlab Corp | $24.73 | 2019 | |
| Dompe US, INC. | $24.53 | 2025 | Oxervate |
| Alimera Sciences, INC. | $23.41 | 2024 | Yutiq, Iluvien |
| Sun Pharmaceutical Industries INC. | $21.14 | 2019 | |
| Amgen INC. | $18.45 | 2025 | Tepezza |
| New World Medical,INC. | $18.07 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $17.64 | 2024 | Tecnis Simplicity |
| Lkc Technologies, INC. | $14.71 | 2024 | |
| Apellis Pharmaceuticals, INC. | $14.27 | 2023 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcpike listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.